onco.fit is the trusted navigation and coordination layer for cancer care in India. Patients get essential guidance free; institutions that benefit when patients reach the right care earlier pay for coordination and measurable outcomes. Revenue grows by making care better organised, not by selling more of it.
onco.fit will not compete with hospitals or specialty clinic networks to own cancer care. It provides the trusted navigation and coordination infrastructure that enables patients to access the most appropriate care across public, charitable and private providers.
Essential cancer-suspicion navigation stays free to the patient. Revenue comes from hospitals, employers, insurers, government programmes and CSR funders who gain when patients reach appropriate care earlier and complete the right diagnostic pathway.
We are paid for referral quality, pathway completion, appointment coordination and quality reporting. We never take bill commissions, diagnostic-volume payments, paid rankings, or lead sales.
Multiple payer types (hospital, employer, insurer, government, CSR) mean revenue is not tied to any single buyer, and institutional relationships renew as outcomes are reported.
Families who want higher-touch help can pay for a dedicated navigator or second-opinion coordination. Ability to pay never changes clinical urgency or pathway.
Cancer care in India is growing, fragmented, and expensive for families. The gap onco.fit fills is coordination, which no hospital owns.
Public estimates (ICMR-NCRP) put annual incidence near 1.4 million and rising with an ageing population and changing risk factors. Directional.
A large share of patients present at an advanced stage and lose time and money moving between reports, hospitals and bills. Cancer is a leading driver of catastrophic out-of-pocket health spending in India.
The region concentrates major public and private cancer centres and draws patients from across north India, making it an efficient first market to prove the model.
Hospitals compete to deliver treatment, not to navigate patients across public, charitable and private providers. That neutral layer is the opportunity.
Market figures are directional, drawn from public sources such as ICMR-NCRP for orientation only. Traction figures are placeholders to be replaced with diligence-backed data. Nothing here is an offer of securities.
The architecture keeps the marginal cost of each new case and each new cancer type low.
Core guidance runs on a rules engine and works without a large language model, so each additional case adds little variable cost. AI is used narrowly, mainly to read document images.
Each cancer pathway is one structured entry in a registry. Ten cancers are live today (breast, lung, cervical, oral and head & neck, colorectal, ovarian, stomach, prostate, esophageal, and blood); adding the next is a content task, not an engineering project.
The same platform is sold to hospitals, employers, insurers, government and CSR funders, so growth is not gated on a single channel.
Guidance is English and Hindi today and is not tied to one city, so expanding from Delhi NCR to other Indian metros is largely a data and partnerships exercise.
Public, enforceable independence (payment never changes clinical guidance) and outcome transparency compound into referral trust that a volume-driven competitor cannot easily copy.
These are the metrics we report to institutional partners. Figures below are placeholders to be replaced with diligence-backed data.
Cumulative and monthly cases navigated.
Signed and piloting sponsors, by payer type.
Completed referrals, time to consultation, and pathway completion.
ARR, contract values, and renewal rate.
The independence rule is permanent. We invite investors to pressure-test it with these questions before they invest.
Free where it must be, paid where institutions receive measurable value, independently governed wherever incentives could touch care. Contact the founding team for the full data room and current traction.